Alzinova AB (publ) (STO:ALZ)

Market Cap	108.25M -32.3%
Revenue (ttm)	149.00K -11.8%
Net Income	-24.32M
EPS	-0.20
Shares Out	316.06M
PE Ratio	n/a
Forward PE	72.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,422,653
Open	0.3400
Previous Close	0.3545
Day's Range	0.3220 - 0.3625
52-Week Range	0.3230 - 2.0700
Beta	1.24
Analysts	n/a
Price Target	1.20 (+250.37%)
Earnings Date	Nov 12, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. The company’s lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alz...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2025, Alzinova AB's revenue was 252,000, an increase of 740.00% compared to the previous year's 30,000. Losses were -26.27 million, 27.8% more than in 2024.

Analyst Summary

The average 12-month stock price target for ALZ is kr 1.20, which is an increase of 250.37% from the latest price.

Price Target

kr 1.20

(250.37% upside)

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 2, 2026

Data Sources Report a data error